Key Takeaways
- Exor transformed from Fiat's origins into a diversified investment holding company.
- John Elkann reshaped Exor, focusing on strategic asset management and financial discipline.
- Exor's stock trades at a significant NAV discount, prompting active capital allocation.
- The company targets long-term growth in healthcare, luxury, and technology sectors.
Deep Dive
- Exor's origins trace back to Giovanni Agnelli's founding of Fiat in the late 19th century.
- By 2009, it formally established its current holding company structure in the Netherlands to simplify family asset management and gain tax benefits.
- Exor's notable assets include Ferrari, CNH, Stellantis, and Philips, alongside smaller listed and private investments.
- The company actively works to close a discount to its sum of parts through asset sales, capital reallocation, and share repurchases.
- John Elkann, nominated heir at 21, assumed leadership around 2003-2004 during a period of financial and operational distress for Exor.
- His leadership included the strategic appointment of Sergio Marchionne as Fiat CEO, who secured $2 billion from General Motors and merged Fiat with Chrysler.
- Exor's formal establishment in 2009 coincided with Fiat's transformation into distinct entities such as Stellantis, CNHI, Iveco, and Ferrari.
- Over the past 15 years, Exor's portfolio has dramatically changed, with only one of its original top four listed investments remaining.
- Ferrari, listed in 2015, has been a significant driver of Exor's Net Asset Value (NAV) growth, with its motor racing connection central to its identity.
- Exor sold approximately $3 billion in Ferrari shares to rebalance its portfolio, comfortable with a 25-30% concentration.
- Current primary holdings also include Stellantis, CNHI (agricultural equipment), and Philips, alongside smaller listed and private investments.
- Exor's stock consistently trades at a significant 50-60% discount to its Net Asset Value (NAV), with listed assets comprising 70% of its base.
- While Ferrari trades at a high multiple, other key listed holdings like Stellantis, CNHI, and Philips face challenging industry cycles and trade at reasonable multiples.
- The market questions the true valuation of both listed and unlisted assets, alongside the appropriate discount for a holding company.
- Juventus, a minor asset, is viewed as a family passion rather than a strategic financial move, while Clarivate is seen as a potential building block for future healthcare and technology focus.
- John Elkann views the NAV discount as an opportunity for Exor to buy back its own stock, evidenced by the strategic trimming of Ferrari shares.
- Exor defines success by per-share growth in Net Asset Value (NAV), benchmarking its performance against the MSCI World index.
- The company maintains strict financial discipline, typically keeping debt between 10-20% of assets, which ensures a stable dividend and allows for offensive investments.
- Exor's investment approach combines an entrepreneurial spirit with financial discipline, emphasizing the identification and empowerment of long-term leaders.
- Exor operates as a 'critical friend' to its portfolio companies, offering support without aggressive ownership.
- Its strong balance sheet, with debt typically between 10-20% of assets, provides a relaxed capital position for both stability and offensive investments.
- The company's private portfolio includes diverse assets such as The Economist, healthcare company Institut Merieux, luxury brand Christian Louboutin, and robotics firm Welltech.
- Exor acquired the reinsurance business Partner E in 2015 for 9 billion and divested it to Coveya approximately six years later, yielding a reported 9-10% Internal Rate of Return (IRR).
- The investment faced challenges due to market aversion to volatility and elevated catastrophe losses during Exor's ownership.
- Despite 'okay' returns, Exor divested the business due to high market multiples for reinsurance companies and a solid offer from Covea, signifying a willingness to change course.
- The transaction led to a longer-term partnership with Coveya for Exor's asset management firm, demonstrating Exor's strategic approach of continuous improvement.
- John Elkann's philosophy emphasizes investing in change while maintaining financial strength, guiding Exor's long-term focus on healthcare, luxury, and technology.
- Exor is building expertise in technology, particularly AI, through initiatives such as the Vento seed program and its ventures business, exemplified by an investment in VIA, an urban mobility optimization company that filed for an IPO.
- John Elkann's recent board membership at Meta provides insights into AI and Silicon Valley connections, reinforcing Exor's long-term thesis in healthcare technology.
- The company's private portfolio and investments in Philips and BioMeru position it in healthcare tech, with significant optionality expected to materialize over the next 5-10 years.